- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02139722
Patient-Centered Care and Asian Americans
A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans
Liver cancer and hepatitis B are health disparities for Asian Americans, and hepatitis C is a rising problem. Little is known about how to improve the quality of health care Asian Americans receive for viral hepatitis. Technology, specifically mobile applications, can provide a flexible and efficient way to address these challenges. This project seeks to develop, implement, and test an intervention to increase hepatitis B and C screening for Asian Americans in 2 healthcare systems in San Francisco.
The research team will develop, implement, and evaluate the efficacy of an interactive, patient- centered mobile app for use on a tablet computer to increase hepatitis B and C screening among unscreened Asian Americans age 18 and older. The team will use their experience in health promotion to develop the intervention by working with patients, community leaders and advocates, clinical staff, healthcare providers, and healthcare system administrators from a county safety net system and an academic primary care practice in the San Francisco Bay Area. The mobile application will include video clips with a physician (Video Doctor) addressing patient concerns regarding hepatitis B and C screening in the patient's preferred language, English, Chinese, or Vietnamese. A patient who has not been screened for hepatitis B will answer questions about his or her characteristics and preferences using the mobile application. The mobile application will then show 30-60 seconds video clips with messages that address the patient's responses related to hepatitis B screening and that are delivered by an actor playing a physician. Those who are born between 1945 and 1965 also receive messages about hepatitis C screening. At the end, the tablet computer will generate a provider alert to let the treating provider know what the patient's preferences are regarding testing for viral hepatitis.
Once developed, the intervention will then be used in combination with a physician panel notification and tested against physician panel notification only in a randomized controlled trial to see which approach is better in increasing the rate of hepatitis B and C screening. The team will also work with the 2 healthcare system to ensure that the interventions will be practical and easily adopted once the study is over. The findings of this project will greatly expand understanding about how to use technology- based interventions to improve quality of healthcare in diverse patient populations.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94143
- University of California, San Francisco
-
San Francisco, California, Förenta staterna, 94110
- Zuckerberg San Francisco General
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- ages 18+ years
- identifies as Asian
- Asian American, Chinese, or Vietnamese
- speaks English, Chinese (Cantonese), or Vietnamese
- does not have an electronic health record (EHR)-documented HBV screening test (defined as a hepatitis B surface antigen [HBsAg] test).
- we select Chinese and Vietnamese because those are the 2 most common languages spoken by limited English-proficient Asian Americans
Exclusion Criteria:
- dementia or any conditions precluding understanding informed consent or using a touch screen with audio
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Undersökning
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Inget ingripande: Provider Panel Notification (PPN) Alone
The comparison procedures consist of a panel notification given to providers and an audio-visual presentation on diet and exercise given to patients.
|
|
Experimentell: Video Doctor, PA + PPN
Video Doctor (VD) and Provider Alert (PA) intervention combined with Provider Panel Notification (PPN)
|
The intervention consists of a Video Doctor and Provider Alert.
For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips.
The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication.
The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
EHR-documented hepatitis B surface antigen (HBsAg) test
Tidsram: 3 months
|
The main outcome measure is an EHR-documented hepatitis B surface antigen (HBsAg) test at 3 months post-intervention.
We chose screening for hepatitis B because, among adults, particularly immigrants or descendants of immigrants, it is the most important first step in the control of viral hepatitis B and lack of screening remains a significant problem.
While many young adult Asian Americans born in the U.S. or who immigrated at a young age may have been vaccinated for hepatitis B as a child or prior to entering college, pre-vaccination testing may not have been done.
Given the high rates of infection in their parents and the possibility of vertical transmission, all Asian Americans should be tested for chronic hepatitis B using the HBsAg test.
All screening outcomes (test receipt) as well as test ordering by the healthcare providers will be collected from the medical record through the EHRs at 3-month post-intervention.
|
3 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Knowledge about hepatitis B virus (HBV) and hepatitis C virus (HCV)
Tidsram: 3 months
|
Data sources include the self-administered pre-intervention survey via a tablet computer, and the post-intervention phone survey administered by a research assistant, and EHR.
All patient surveys will be done in the patient's preferred language (English, Chinese, or Vietnamese).
Pre- and post-intervention survey data of secondary outcomes include: Knowledge (awareness of HBV and HCV, screening test, modes of transmission); Self-efficacy (perceived confidence in initiating conversation and request screening test from providers); Patient-Provider Communication Experiences (asked provider for HBV or HCV test, discussed HBV or HCV test with provider, receipt of provider recommendation to get a HBV or HCV test).
|
3 months
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Tung T Nguyen, MD, University of California, San Francisco
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Flaviviridae-infektioner
- Hepatit, Viral, Human
- Hepadnaviridae-infektioner
- DNA-virusinfektioner
- Enterovirusinfektioner
- Picornaviridae-infektioner
- Leversjukdomar
- Hepatit B
- Hepatit
- Hepatit A
- Hepatit C
Andra studie-ID-nummer
- AD-11-4615
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hepatit B
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeÅterkommande diffust stort B-cellslymfom aktiverat B-cellstyp | Refraktärt diffust stort B-cellslymfom aktiverat B-cellstypFörenta staterna, Saudiarabien
-
Nathan DenlingerBristol-Myers SquibbRekryteringB-cells non-Hodgkin lymfom - återkommande | Diffust stort B-cellslymfom - återkommande | Follikulärt lymfom - återkommande | Höggradigt B-cellslymfom - återkommande | Primärt mediastinalt stort B-cellslymfom - återkommande | Transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort... och andra villkorFörenta staterna
-
Northwestern UniversityNational Cancer Institute (NCI)Aktiv, inte rekryterandeDiffust stort B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Höggradigt B-cellslymfom, ej specificerat på annat sätt | T-cell/Histiocyt-rik stort B-cellslymfom | Höggradigt B-cellslymfom med MYC och BCL2 och/eller BCL6 omarrangemang | Diffust stort B-cellslymfom aktiverat... och andra villkorFörenta staterna
-
Nanfang Hospital of Southern Medical UniversityRekryteringB-cellslymfom | B-cells akut lymfoblastisk leukemi | B-cellsleukemi | B-cellslymfom refraktär | B-cellslymfom ÅterkommandeKina
-
Lapo AlinariRekryteringÅterkommande höggradigt B-cellslymfom med MYC, BCL2 och BCL6 omarrangemang | Refraktärt höggradigt B-cellslymfom med MYC, BCL2 och BCL6 omarrangemang | Återkommande höggradigt B-cellslymfom med MYC och BCL2 eller BCL6 omarrangemang | Refraktärt höggradigt B-cellslymfom med MYC och BCL2 eller... och andra villkorFörenta staterna
-
Athenex, Inc.RekryteringB-cells lymfom | CLL/SLL | ALLA, barndom | DLBCL - Diffust stort B-cellslymfom | B-cell leukemi | NHL, Återfall, Vuxen | ALL, vuxen B-cellFörenta staterna
-
Ohio State University Comprehensive Cancer CenterRekryteringDiffust stort B-cellslymfom | Höggradigt B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Diffust stort B-cellslymfom Germinalt centrum B-cellstypFörenta staterna
-
Curocell Inc.RekryteringHöggradigt B-cellslymfom | Diffust stort B-cellslymfom (DLBCL) | Primärt mediastinalt stort B-cellslymfom (PMBCL) | Transformerat follikulärt lymfom (TFL) | Refraktärt stort B-cellslymfom | Återfall av stort B-cellslymfomKorea, Republiken av
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenAktiv, inte rekryterandeÅterkommande diffust stort B-cellslymfom | Refraktärt diffust stort B-cellslymfom | CD20 positiv | Steg I diffust stort B-cellslymfom | Steg II diffust stort B-cellslymfom | Steg III Diffust stort B-cellslymfom | Steg IV Diffust stort B-cellslymfomFörenta staterna
-
University of ChicagoMerck Sharp & Dohme LLCRekryteringLymfom | Lymfom, B-cell | B-cellslymfom | Diffust stort B-cellslymfom | Höggradigt B-cellslymfomFörenta staterna